Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Child Disruptive Behavior Disorders Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)

NCT00221962
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
8 Years to 12 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 14, 2014 · Synced Sep 17, 2026, 5:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Johnston County ADHD Study: Environmental, Reporductive, and Familial Risk Factors for Attention-Deficit Hyperactivity Disorder (ADHD)

NCT00339729
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
8 Years and older
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2007
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 17, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

NCT03325881
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
41
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 17, 2026, 5:11 AM EDT
Recruiting Phase 4 Interventional

Treating Young Children With Attention Deficit Hyperactivity Disorder

NCT07300956
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Guanfacine (GUA), Methylphenidate (MPH)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 5 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Palo Alto, California • Boston, Massachusetts • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 17, 2026, 5:11 AM EDT
Not yet recruiting No phase listed Observational

Psychotherapy for Irritability in Youth: Comparing Active Treatment to Nonactive Psychoeducation Supportive Psychotherapy

NCT07640802
View directory record Official record
Conditions
Irritability, Disruptive Mood Dysregulation Disorder, Oppositional Defiant Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Psychotherapy
Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 17 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 17, 2026, 5:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Long-Duration Stimulant Treatment Study of ADHD in Young Children

NCT00257725
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
B-MPH
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
4 Years to 5 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Sep 17, 2026, 5:11 AM EDT
Not listed Phase 4 Interventional

Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents

NCT00252278
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD), Insomnia
Interventions
atomoxetine
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 6, 2006 · Synced Sep 17, 2026, 5:11 AM EDT
Completed Not applicable Interventional Results available

Mobile Behavioral Parent Training for Childhood ADHD: A Micro-randomized Trial

NCT06012851
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Mobile behavioral parent training (mBPT), In the moment feedback, In the moment suggestions
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
7 Years to 12 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 17, 2026, 5:11 AM EDT
Completed Not applicable Interventional

Central Executive Training for ADHD

NCT03042338
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
CET: Central Executive Training, CET: Comparison Executive Training
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
8 Years to 13 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 17, 2026, 5:11 AM EDT
Completed Not applicable Interventional

Evaluation of Regulation Focused Psychotherapy for Children

NCT03594253
View directory record Official record
Conditions
Oppositional Defiant Disorder, Oppositional Defiant Disorder in Children
Interventions
Regulation Focused Psychotherapy for Children
Behavioral
Lead sponsor
Yeshiva University
Other
Eligibility
5 Years to 12 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 17, 2026, 5:11 AM EDT
Completed Not applicable Interventional

Child and Family Outcomes and Consumer Satisfaction for Online vs Staff-Delivered Parenting Intervention

NCT02121431
View directory record Official record
Conditions
Childhood Disruptive Behavior Disorders, Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit Hyperactivity Disorder, Parent-Child Interactions
Interventions
Triple P--Positive Parenting Program
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
3 Years to 7 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Eugene, Oregon • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 17, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

KP415 Classroom Study in Children (6-12 Years of Age) With ADHD

NCT03292952
View directory record Official record
Conditions
ADHD
Interventions
KP415 oral capsule, Placebo oral capsule
Drug
Lead sponsor
Zevra Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 17, 2026, 5:11 AM EDT
Completed Not applicable Interventional

Evaluating an Online Parenting Support System Disseminated by Pediatric Practices

NCT02064452
View directory record Official record
Conditions
Child Disruptive Behavior Disorders, Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Triple P Online System, Placebo Comparator
Other · Behavioral
Lead sponsor
Oregon Research Institute
Other
Eligibility
3 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Eugene, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 17, 2026, 5:11 AM EDT
Completed Not applicable Interventional

Evaluation of a Video-Based Media Series to Promote Effective Parenting

NCT00611832
View directory record Official record
Conditions
Childhood Disruptive Behavior Problems
Interventions
Triple P Media Series -- Standard "Information-Only" version, Triple P Media Series -- Enhanced "Behavior Activation" version
Behavioral
Lead sponsor
Oregon Research Institute
Other
Eligibility
20 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Sep 17, 2026, 5:11 AM EDT
Completed Not applicable Interventional

Habit Reversal Training for Children and Adolescents With Trichotillomania

NCT01445444
View directory record Official record
Conditions
Trichotillomania
Interventions
Habit Reversal Training
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
7 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Sep 17, 2026, 5:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Brain Training in Children With/At-risk for Attention-Deficit/Hyperactivity Disorder and Executive Function Impairment

NCT02588365
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Brain Training (Active), Brain Training (Passive), Brain Training (Active or Passive)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 5 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 17, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD

NCT01239030
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
Methylphenidate Hydrochloride Extended Release Capsules, Placebo
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
6 Years to 18 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
16
States / cities
Little Rock, Arkansas • Irvine, California • National City, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 17, 2026, 5:11 AM EDT
Completed Phase 4 Interventional Results available

Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children

NCT00183391
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine, Methylphenidate
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
6 Years to 17 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 17, 2026, 5:11 AM EDT
Enrolling by invitation Phase 3 Interventional

An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD

NCT07773883
View directory record Official record
Conditions
ADHD
Interventions
Solriamfetol
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
6 Years to 18 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Dothan, Alabama • Maitland, Florida • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 17, 2026, 5:11 AM EDT
Completed Phase 4 Interventional Results available

Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD

NCT01709695
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine Hydrochloride XR, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
8 Years to 15 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 17, 2026, 5:11 AM EDT
Completed Phase 3 Interventional

A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

NCT05428033
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
centanafadine capsule, placebo capsule
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 17, 2026, 5:11 AM EDT
Completed Not applicable Interventional

Evaluating the Feasibility of Internet-delivered PCIT

NCT03260725
View directory record Official record
Conditions
Oppositional Defiant Disorder, Conduct Disorder, Disruptive Behavior Disorder Nos
Interventions
Parent-Child Interaction Therapy (PCIT), Internet-delivered PCIT (I-PCIT)
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
3 Years to 5 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Sep 17, 2026, 5:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Risk of Attention Deficit Hyperactivity Disorder (ADHD) in the Children of Adults With ADHD Not Otherwise Specified (NOS)

NCT00181857
View directory record Official record
Conditions
ADHD
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 17, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study

NCT03088267
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
amphetamine extended-release oral suspension, 2.5 mg/mL, Placebo extended-release oral suspension
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Sep 17, 2026, 5:11 AM EDT